Linked Life Data

363642

Source:http://linkedlifedata.com/resource/pubmed/id/363642

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
1979-2-21
pubmed:abstractText
The clinical effects of a new cardioselective beta-adrenergic blocking drug, acebutolol hydrochloride (SECTRAL), were studied in 18 patients with angina pectoris, using graded treadmill testing according to a modified Bruce protocol. Measurements were made in the control state, after two weeks' treatment with placebo and after two more weeks of constant oral dose of the drug. Acebutolol produced a significant increase in the treadmill work performed before the onset of ischemic ECG changes and chest pain. The heart rate and blood pressure responses to exercise were depressed, so that the greater work load was achieved at a lower double product. Graded treadmill testing is a useful method for assessing the efficacy of treatment with a beta-blocking drug.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0021-2180
pubmed:author
pubmed:issnType
Print
pubmed:volume
14
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
941-7
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1978
pubmed:articleTitle
Acebutolol in angina pectoris: objective assessment using graded treadmill testing.
pubmed:publicationType
Journal Article, Clinical Trial